Barclays PLC raised its stake in shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV – Free Report) by 303.1% during the third quarter, HoldingsChannel reports. The firm owned 47,655 shares of the biopharmaceutical company’s stock after purchasing an additional 35,832 shares during the quarter. Barclays PLC’s holdings in Achieve Life Sciences were worth $226,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds have also bought and sold shares of ACHV. Geode Capital Management LLC boosted its holdings in shares of Achieve Life Sciences by 6.9% in the 3rd quarter. Geode Capital Management LLC now owns 749,109 shares of the biopharmaceutical company’s stock valued at $3,552,000 after acquiring an additional 48,474 shares during the last quarter. State Street Corp boosted its holdings in shares of Achieve Life Sciences by 6.8% in the 3rd quarter. State Street Corp now owns 431,520 shares of the biopharmaceutical company’s stock valued at $2,045,000 after acquiring an additional 27,419 shares during the last quarter. Verition Fund Management LLC purchased a new stake in shares of Achieve Life Sciences in the 3rd quarter valued at $113,000. MetLife Investment Management LLC boosted its holdings in shares of Achieve Life Sciences by 65.6% in the 3rd quarter. MetLife Investment Management LLC now owns 14,993 shares of the biopharmaceutical company’s stock valued at $71,000 after acquiring an additional 5,939 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new stake in shares of Achieve Life Sciences in the 3rd quarter valued at $54,000. Institutional investors and hedge funds own 33.52% of the company’s stock.
Achieve Life Sciences Stock Down 7.8 %
Shares of Achieve Life Sciences stock opened at $2.85 on Wednesday. The company has a market cap of $98.01 million, a P/E ratio of -2.52 and a beta of 1.66. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.78 and a current ratio of 6.78. Achieve Life Sciences, Inc. has a one year low of $2.84 and a one year high of $5.59. The firm has a fifty day moving average of $3.94 and a two-hundred day moving average of $4.42.
Wall Street Analyst Weigh In
ACHV has been the topic of a number of recent analyst reports. Rodman & Renshaw initiated coverage on shares of Achieve Life Sciences in a report on Thursday, November 14th. They set a “buy” rating and a $12.00 price target on the stock. Raymond James initiated coverage on shares of Achieve Life Sciences in a report on Friday, September 27th. They set a “strong-buy” rating and a $20.00 price target on the stock. Finally, RODMAN&RENSHAW raised shares of Achieve Life Sciences to a “strong-buy” rating in a report on Thursday, November 14th. Four research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $14.80.
Check Out Our Latest Analysis on Achieve Life Sciences
About Achieve Life Sciences
Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.
Read More
- Five stocks we like better than Achieve Life Sciences
- Are Penny Stocks a Good Fit for Your Portfolio?
- SAP’s Strong Momentum: A Bullish Setup for Investors
- What is a SEC Filing?
- BlackRock Breaks Records: Why the Stock Still Has Room to Run
- What Are Trending Stocks? Trending Stocks Explained
- Duke vs. NRG: Which Energy Stock Will Power Higher Gains?
Want to see what other hedge funds are holding ACHV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Achieve Life Sciences, Inc. (NASDAQ:ACHV – Free Report).
Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.